DM
SUPN icon

Deerfield Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Deerfield Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,331
Closed -$255K – 174
2025
Q3 		$255K Buy
+5,331
New +$215K ﹤0.01% 140
2024
Q2 		– Sell
-6,654
Closed -$227K – 555
2024
Q1 		$227K Sell
6,654
-5,352
-45% -$159K ﹤0.01% 312
2023
Q4 		$347K Buy
+12,006
New +$318K 0.01% 103

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management's SUPN Position: Q4 2025 in Review

Deerfield Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 5,331 shares — an estimated $255K sold.

Deerfield Management first reported a position in SUPN in Q4 2023 and held it in 3 quarters. The position peaked at $347K in Q4 2023. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Deerfield Management reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Deerfield Management sold 5,331 Supernus Pharmaceuticals shares in Q4 2025, an estimated $255K.
  • Deerfield Management first reported a position in Supernus Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Deerfield Management's Supernus Pharmaceuticals position peaked at $347K in Q4 2023.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Deerfield Management's 13F filing for Q4 2025, filed 17 Feb 2026.